Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Sunitinib

Study 1

Pfizer · Phase 3 · Completed · Enrollment 361

NCT00075218

ArmPopulationDoseEstimandComparatorEfficacy
Sunitinib 50 mg, 4 weeks on 2 offGIST after imatinib progression or intolerance50 mgITTplacebomedian time to tumor progression: 27.3 weeks, interim analysismedian progression-free survival: 24.1 weeks, interim analysisobjective response rate (partial responses): 6.8%, interim analysis
PlaceboGIST after imatinib progression or intoleranceplaceboITTn/rmedian time to tumor progression: 6.4 weeks, interim analysismedian progression-free survival: 6 weeks, interim analysis